Oxygénothérapie de longue durée : survie à 1 an, facteurs prédictifs de mortalité

Cauwenberge, H. Van; Thonnard, Anne-Sophie; Dang, Delphine Nguyen; Corhay, Jean-Louis; Louis, Renaud

doi:10.1016/j.rmr.2018.09.001

Cited by 2 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, continuous home oxygen therapy (HOT) reduces the risk of poor prognosis. Although HOT is known to increase survival, reduce admission rates and improve the quality of life in patients with COPD and chronic respiratory failure [37,38], the relationship between HOT and patient progress following an AECOPD episode is not clearly defined. Recent literature shows apparently contradictory results in the relationship between HOT and prognosis after AECOPD: mortality, admission rate and average stay increase according to some studies [39][40][41]; and patients with HOT would show higher survival rates after admission to ICU and lower admission numbers according to other authors [42,43].…”

Section: Discussionmentioning

confidence: 99%

Impact of Hyponatremia on COPD Exacerbation Prognosis

García-Sanz¹,

Martínez-Gestoso²,

Calvo-Álvarez

et al. 2020

JCM

View full text Add to dashboard Cite

The most common electrolyte disorder among hospitalized patients, hyponatremia is a predictor of poor prognosis in various diseases. The aim of this study was to establish the prevalence of hyponatremia in patients admitted for acute exacerbation of chronic obstructive pulmonary disease (AECOPD), as well as its association with poor clinical progress. Prospective observational study carried out from 1 October 2016 to 1 October 2018 in the following hospitals: Salnés in Vilagarcía de Arousa, Arquitecto Marcide in Ferrol, and the University Hospital Complex of Santiago de Compostela, Galicia, Spain, on patients admitted for AECOPD. Patient baseline treatment was identified, including hyponatremia-inducing drugs. Poor progress was defined as follows: prolonged stay, death during hospitalization, or readmission within one month after the index episode discharge. 602 patients were enrolled, 65 cases of hyponatremia (10.8%) were recorded, all of a mild nature (mean 131.6; SD 2.67). Of all the patients, 362 (60%) showed poor progress: 18 (3%) died at admission; 327 (54.3%) had a prolonged stay; and 91 (15.1%) were readmitted within one month after discharge. Patients with hyponatremia had a more frequent history of atrial fibrillation (AF) (p 0.005), pleural effusion (p 0.01), and prolonged stay (p 0.01). The factors independently associated with poor progress were hyponatremia, pneumonia, and not receiving home O2 treatment prior to admission. Hyponatremia is relatively frequent in patients admitted for AECOPD, and it has important prognostic implications, even when mild in nature.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Hyponatremia on COPD Exacerbation Prognosis

García-Sanz¹,

Martínez-Gestoso²,

Calvo-Álvarez

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…COPD is also characterized by systemic inflammation and extra-pulmonary manifestations, such as osteoporosis [ 2 ]. As in the general population, osteoporosis is linked with mortality and morbidity in COPD patients: lower T-scores are associated with a 5% increase in mortality [ 3 ], fractures are linked with higher mortality [ 4 ] and retrospective analysis of our local COPD cohort identifies osteoporosis as a mortality risk factor among patients receiving long-term oxygen therapy [ 5 ]. Morbidity is increased with higher hospitalization rates [ 4 ] and a decline in lung function is associated with vertebral fractures [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Lung Function Impairment, Associating Hyperinflation with Impaired Diffusion Capacity and Transfer Coefficient, Is a Risk Factor for Hip Osteoporosis in Patients with Chronic Obstructive Pulmonary Disease

Malaise

André

Durme

et al. 2023

JCM

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a risk factor for osteoporosis. Our objective is to determine if functional indices associated with emphysema on pulmonary function tests (DLCO—diffusion capacity of the lung for CO-; DLCO/AV—DLCO corrected for alveolar volume- and TLC—total lung capacity), considered alone or together, can identify COPD patients with osteoporosis. Methods: 90 COPD patients underwent dual-energy X-ray absorptiometry (DEXA) and pulmonary function tests. Results: 26% of the COPD patients were osteoporotic. In univariate analysis, each functional parameter associated with emphysema, analyzed separately, was not associated with osteoporosis. In contrast, patients with hyperinflation associated with impaired diffusion capacity and transfer coefficient, defined by the association of the three functional indices (DLCO < 70%, DLCO/AV < 80% and CPT > 115%), had significantly more osteoporosis at the total hip (OR: 5.9, CI: 1.5–23.8, p = 0.013). In multivariate analysis, this phenotype was confirmed as an independent factor associated with hip osteoporosis. In contrast, COPD airway obstruction severity, based on FEV1 (%), was not associated with osteoporosis. A lower BMI, female gender and age were also identified as osteoporosis risk factors. Conclusions: COPD patients with hyperinflation associated with impaired diffusion capacity and transfer coefficient are at higher risk for osteoporosis. Pulmonary function tests associated with emphysema detection can help to identify COPD patients with osteoporosis, in addition to the classical risk factors.

show abstract

Oxygénothérapie de longue durée : survie à 1 an, facteurs prédictifs de mortalité

Cited by 2 publications

References 25 publications

Impact of Hyponatremia on COPD Exacerbation Prognosis

Impact of Hyponatremia on COPD Exacerbation Prognosis

Lung Function Impairment, Associating Hyperinflation with Impaired Diffusion Capacity and Transfer Coefficient, Is a Risk Factor for Hip Osteoporosis in Patients with Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About